4//SEC Filing
Biota Pharmaceuticals, Inc. 4
Accession 0001209191-13-055958
$VXRTCIK 0000072444operating
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 5:53 PM ET
Size
8.6 KB
Accession
0001209191-13-055958
Insider Transaction Report
Form 4
PATTI JOSEPH M
EVP, Corporate Dev & Strategy
Transactions
- Award
Stock Option (Right to Buy)
2013-12-05+62,500→ 62,500 totalExercise: $4.13Exp: 2023-12-05→ Common Stock (62,500 underlying) - Award
Market Stock Units
2013-12-05+15,625→ 15,625 total→ Common Stock (15,625 underlying)
Footnotes (3)
- [F1]This option is a performance based option that will be 100% vested and exercisable upon hitting the primary endpoint for the Issuer's Phase 2 IGLOO trial on or before June 30, 2015, as determined by the Issuer's Compensation Committee in its sole discretion.
- [F2]Each Market Stock Unit (MSU) represents a right to receive up to 2.5 shares of the Issuer's common stock. The vesting amount will be determined based on the twenty day trailing average stock price of the Issuer's common stock measured as of the last day of the performance period beginning on December 5, 2013 and ending on January 1, 2017.
- [F3]Unless earlier forfeited under the terms of the MSU or accelerated upon a change of control transaction, each MSU vests and converts into no more than 2.5 shares of the Issuer's common stock on January 1, 2017.
Documents
Issuer
Biota Pharmaceuticals, Inc.
CIK 0000072444
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000072444
Filing Metadata
- Form type
- 4
- Filed
- Dec 8, 7:00 PM ET
- Accepted
- Dec 9, 5:53 PM ET
- Size
- 8.6 KB